2019-004403-12: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study Essai clinique de phase II multicentrique évaluant le talimogene laherparepvec dans la maladie de Kaposi classique ou endémique |
|
|
| Not yet recruiting | 2 | 20 | Europe | talimogene laherparepvec, Solution for injection, Imlygic | ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS, Amgen | The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS traitement par T-Vec de patients atteints du Sarcome de Kaposi., Diseases [C] - Cancer [C04] | | | | |
NCT02923778: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery |
|
|
| Active, not recruiting | 2 | 40 | Canada, US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC | National Cancer Institute (NCI) | Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 40 | US | Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], TVEC, Imlygic, Nivolumab IV Soln 100 MG/10ML, Opdivo, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution, Yondelis | Sarcoma Oncology Research Center, LLC | Sarcoma | 12/24 | 03/25 | | |
NCT03069378: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
|
|
| Active, not recruiting | 2 | 41 | US | Talimogene Laherparepvec (T-VEC), Pembrolizumab | Memorial Sloan Kettering Cancer Center, Amgen, Merck Sharp & Dohme LLC | Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma | 03/25 | 03/25 | | |
